However, recent studies showed that BRAF and NRAS mutations can co-occur in some melanoma cells of BRAF-resistant patients, and their presence is associated with a heterogeneous and variable response to different types of inhibitors of MEK, ERK, PI3K, and AKT [31]. This evidence concerns the gene MAP2K7 and melanoma.